PhRMA names new chief medical officer, EVP

WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Wednesday announced Richard Moscicki will join the organization as chief medical officer and EVP. He will lead the organization's science and regulatory advocacy efforts beginning in early October 2017.



"I am pleased to welcome Rich to the helm of our science and regulatory team," stated Stephen Ubl, president and CEO of PhRMA. "Rich's deep medical, academic, clinical regulatory and private sector expertise will be invaluable as we seek to advance public policies in the United States and around the world that support medical innovation."



A recognized expert in clinical research and development, Moscicki joins PhRMA from the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, where he served as deputy center director for science operations. He provided executive direction of Center operations and leadership in overseeing the development, implementation and direction of CDER's programs.



Before joining CDER, Moscicki was SVP, head of clinical development and chief medical officer at Genzyme Corporation. For nearly two decades at Genzyme, Moscicki was responsible for worldwide global regulatory and pharmacovigilance matters, clinical research and medical affairs.



"We are in an unprecedented era of biopharmaceutical innovation that is developing next-generation cures that will transform patient care for serious diseases such as Alzheimer's, ALS and cancer," Moscicki said. "I am pleased to join PhRMA at a time when the regulatory environment around these potential new treatments is only growing more dynamic and complex."



Moscicki received his medical degree from Northwestern University Medical School and is board certified in internal medicine, diagnostic and laboratory immunology, and allergy and immunology. Moscicki previously served on staff at Massachusetts General Hospital and on the faculty of Harvard Medical School.